Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김수경 | * |
dc.date.accessioned | 2022-03-31T16:31:20Z | - |
dc.date.available | 2022-03-31T16:31:20Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 1550-8080 | * |
dc.identifier.other | OAK-31246 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/261058 | - |
dc.description.abstract | OBJECTIVE: The ROP-ESAT6-CFP10 antigen (Changzhou Niujin Shisong Biotech [CBI], China) was recently developed using recombinant overlapping peptide (ROP) technology. We used ROP-ESAT6-CFP10 as a tuberculosis (TB)-specific antigen and compared it with existing interferon-gamma release assays (IGRAs). METHODS: Healthy volunteers and patients who were diagnosed with TB within a one-year period were enrolled. Samples were tested with QuantiFERON-TB Gold (QFT; QIAGEN Sciences Inc., USA), T-SPOT.TB (Oxford Immunotec, UK), and ELISpot using ROP-ESAT6-CFP10 as a TB-specific antigen (ROP-TB). For ROP-TB, two concentrations (1 μg and 5 μg) of ROP-ESAT6-CFP10 were used as TB-specific antigens. Agreement between assays was evaluated. RESULTS: A total of 35 TB patients and 20 healthy volunteers were evaluated. Agreement between T-SPOT.TB and ROP-TB 1 μg, QFT and ROP-TB 1 μg, and ROP-TB 1 μg and ROP-TB 5 μg/mL were 79.1% (kappa=0.483), 76.7% (kappa=0.557), and 95.3% (kappa=0.894), respectively. The median number of spots between the T-SPOT.TB and ROP-TB assays in the TB patients had no significant difference. CONCLUSIONS: ELISpot using newly developed ROP-ESAT6-CFP10 showed good agreement with T-SPOT.TB and QFT. Since ROP technology can lower the manufacturing cost, ROP-ESAT6-CFP10 might work as a good source of TB-specific antigen for IGRAs. Copyright © 2022 by the Association of Clinical Scientists, Inc. | * |
dc.language | English | * |
dc.publisher | NLM (Medline) | * |
dc.subject | Interferon gamma release assay | * |
dc.subject | Latent tuberculosis infection | * |
dc.subject | Overlapping peptide | * |
dc.title | ROP-ESAT6-CFP10 as Tuberculosis-Specific Antigen in Interferon Gamma Release Assay | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 52 | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 126 | * |
dc.relation.lastpage | 132 | * |
dc.relation.journaltitle | Annals of clinical and laboratory science | * |
dc.identifier.scopusid | 2-s2.0-85124923210 | * |
dc.author.google | Kim M.J. | * |
dc.author.google | Ha E.-H. | * |
dc.author.google | Lee Y.-K. | * |
dc.author.google | Park S.J. | * |
dc.author.google | An C.H. | * |
dc.author.google | Park S.-Y. | * |
dc.author.google | Kim S.-K. | * |
dc.contributor.scopusid | 김수경(56013474600;57960989400;58619290500) | * |
dc.date.modifydate | 20240318142540 | * |